Delivering next generation treatments for vitreo-retinal disorders, with focus on diabetic eye disease

Focus on patients

Focus on vitreo-retinal disorders

ThromboGenics aims at helping patients around the world by developing new or better treatments for their eye conditions

Read more



ThromboGenics’ JETREA®, is the first and only pharmacologic treatment for symptomatic vitreomacular adhesion/vitreomacular traction

Read more



ThromboGenics is listed on the Eurolist by Euronext Brussels under the symbol THR

Read more


You can find us at one of our global locations

Find us

You can also contact us via this web site

Contact us

Annual Report

Thrombogenics Annual Report 2017 - Cover

Annual Report 2017

Stay in touch

Click the button below to receive information about ThromboGenics